Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.67 |
| ▸ | MEN1 | O00255 | 3/20 | 0.67 |
| ▸ | CTSV | O60911 | 2/20 | 0.61 |
| ▸ | CTSL | P07711 | 2/20 | 0.61 |
| ▸ | MYC | P01106 | 1/20 | 0.58 |
| ▸ | MAX | P61244 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.52 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | CDK2 | P24941 | 2/20 | 0.50 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.49 |
| ▸ | ANO2 | Q9NQ90 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22720188 | 0.92 | MAPT (0.74) | MAPTKMT2AMEN1CTSVCTSL | |
| SCHEMBL10623543 | 0.84 | KMT2A (0.64) | MAPTKMT2AMEN1CTSVCTSL | |
| SCHEMBL10623676 | 0.83 | MAPT (0.62) | MAPTKMT2AMEN1CTSVCTSL | |
| SCHEMBL2920267 | 0.83 | CTSV (0.69) | MAPTKMT2AMEN1CTSVCTSL | |
| SCHEMBL3032132 | 0.82 | MAPT (0.71) | MAPTKMT2AMEN1CTSVCTSL | |
| SCHEMBL3020359 | 0.81 | MAPT (0.79) | MAPTKMT2AMEN1CTSVCTSL | |
| SCHEMBL20107846 | 0.81 | MAPT (0.50) | MAPTKMT2AMEN1CTSVCTSL | |
| SCHEMBL3034237 | 0.81 | KMT2A (0.66) | MAPTKMT2AMEN1CTSVCTSL | |
| SCHEMBL5678051 | 0.81 | MAPT (0.60) | MAPTKMT2AMEN1CTSVCTSL | |
| SCHEMBL20107849 | 0.79 | MEN1 (0.46) | MAPTKMT2AMEN1CTSVCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210654-A1 | NOVEL P2Y12 RECEPTOR ANTAGONISTS | RHEINISCHE FRIEDRICH-WILHELMS UNIVERSITÄT BONN (DE) | 2010-08-19 | — | — | US | disclosed |
| US-20100210654-A1 | NOVEL P2Y12 RECEPTOR ANTAGONISTS | RHEINISCHE FRIEDRICH-WILHELMS UNIVERSITÄT BONN (DE) | 2010-08-19 | — | — | US | disclosed |
| US-20100210654-A1 | NOVEL P2Y12 RECEPTOR ANTAGONISTS | RHEINISCHE FRIEDRICH-WILHELMS UNIVERSITÄT BONN (DE) | 2010-08-19 | — | — | US | disclosed |
| EP-2129653-A2 | NOVEL P2Y12 RECEPTOR ANTAGONISTS | Rheinische Friedrich-Wilhelms-Universität Bonn (DE) | 2009-12-09 | — | — | EP | disclosed |
| WO-2008107211-A2 | NOVEL P2Y12 RECEPTOR ANTAGONISTS | RHEINISCHE FRIEDRICH-WILHELMS UNIVERSITÄT BONN (DE) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008107211-A2 | NOVEL P2Y12 RECEPTOR ANTAGONISTS | RHEINISCHE FRIEDRICH-WILHELMS UNIVERSITÄT BONN (DE) | 2008-09-12 | — | — | WO | disclosed |
| EP-1967513-A1 | Novel P2Y12 receptor antagonists | Rheinische Friedrich-Wilhelms-Universität Bonn (DE) | 2008-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210654-A1 | NOVEL P2Y12 RECEPTOR ANTAGONISTS | P2RY12, P2RY11, P2RY13 | MAPT 4617/4885KMT2A 4366/4885MEN1 3506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.